Display Settings:

Format

Send to:

Choose Destination
    Vaccine. 2006 Mar 15;24(12):2176-85. Epub 2005 Nov 10.

    Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

    Source

    Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450, USA. kwang@proteinsciences.com

    Abstract

    Numerous human infections with avian influenza viruses in Asia in recent years have raised the concern that the next influenza pandemic is imminent. The most effective way to combat influenza is through the vaccination of the public. However, a minimum of 3-6 months is needed to develop an influenza vaccine using the traditional egg-based vaccine approach. The influenza hemagglutinin protein (HA), the active ingredient in the current vaccine, can be expressed in insect cells using the baculovirus expression vector system and purified rapidly. An influenza vaccine based on such a recombinant antigen allows a more timely response to a potential influenza pandemic. Here, we report an innovative monitoring assay for recombinant HA (rHA) expression and a rapid purification process. Various biochemical analyses indicate that the purified rHA is properly folded and biologically active.

    PMID:
    16310896
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk